Category Archives: Muscular Dystrophy Treatment

SAN FRANCISCO, March 02, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (FGEN) today reported financial results for the fourth quarter and full year of 2019 and provided an update on the companys recent developments Continue reading →

Pharmacia & Upjohn LLC Duchenne Muscular Dystrophy Treatment Market: Competitive Landscape The competitive landscape is a must for market participants to withstand the competition in the Duchenne Muscular Dystrophy Treatment market. This helps market participants to develop effective strategies to optimize their market positions Continue reading →

About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency, and APOL1-mediated kidney disease. Continue reading →

Babies born to mothers above 35 years of age, the previous child having a birth defect and a family history raise the possibility of children born with congenital conditions, according to a fetal medicine specialist. The other contributing factors are mothers having medical conditions such as uncontrolled diabetes before conception and during pregnancy, congenital heart disease, the effect of taking certain medications, and smoking and drinking among expecting mothers. The vice-chancellor of state-run Srimanta Sankaradeva University of Health Sciences, Dr Dipika Deka, said this in a statement on the occasion of World Birth Defects Day (WBDD). Continue reading →

GRENOBLE, France and RESEARCH TRIANGLE PARK, N.C., March 02, 2020 (GLOBE NEWSWIRE) -- CYTOO, a leading drug discovery company on muscle disorders, today announced that it has entered into a research collaboration aimed at selecting a gene therapy candidate for a rare muscle disorder withAsklepios BioPharmaceutical, Inc.(AskBio), a clinical-stage, fully integrated adeno-associated virus (AAV) gene therapy company. Under the terms of the agreement, AskBio and CYTOO will work together to develop an AAV-based screening platform derived from patient cells. The goal of the collaboration is to screen and select a preclinical candidate capable of restoring a healthy phenotype from patient cells culturedin vitro. Continue reading →

-- The Company will award up to 20 academic scholarships to individuals diagnosed with Duchenne muscular dystrophy -- CAMBRIDGE, Mass., Feb. Continue reading →

MLB teams struggle to keep their players on the field. Perhaps its time to re-consider the controlled use of steroids to avoid and quickly heal injuries. Major League Baseball (MLB) athletes are, of course, not immune from injuries. Continue reading →

Ms. Continue reading →

CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- WAVE Life Sciences Ltd. Continue reading →

MELBOURNE, Australia--(BUSINESS WIRE)--Antisense Therapeutics Limited (ASX:ANP) is pleased to advise of the appointment of Gil Price M.D. as Consultant Medical Director. Dr Continue reading →